Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development candidate for each program

Related Keywords

Ireland ,Dublin ,Scott Jackson ,Madam Cutler ,Dave Borah ,Vicki Goodman ,Smithkline Beecham ,Benjamin Hickey ,Eli Lilly ,Maiken Keson Brookes ,Dsusan Altschuller ,Glympse Bio ,Caroline Loew ,Arthur Cox ,Ym Biosciences ,Forum Pharmaceuticals ,Nasdaq ,Jazz Pharmaceuticals ,Linkedin ,Alkermes ,Goodwin Procter ,Imclone Systems ,Celator Pharmaceuticals ,Exchange Commission On ,Investor Relations Corporate Affairs ,Schering Plough Research Institute ,Mural Oncology ,Nasdaq Global Market ,Bristol Myers Squibb ,General Counsel ,Cerevel Therapeutics ,Schering Plough Research ,Private Securities Litigation Reform Act ,Registration Statement Form ,Exchange Commission ,Investor Relations ,Chief Executive Officer ,Protein Engineering ,Senior Vice President ,Checkpoint Inhibitors ,Mural ,Mmunotherapies ,